Literature DB >> 17589904

Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis.

Ilker Tasci1, Mehmet Refik Mas, Sevil Atalay Vural, Salih Deveci, Bilgin Comert, Gunay Alcigir, Nuket Mas, Cemal Akay, Mithat Bozdayi, Cihan Yurdaydin, Hakan Bozkaya, Ozden Uzunalimoglu, Ahmet Turan Isik, Harun M Said.   

Abstract

AIM: To investigate the antifibrotic effects of peginterferon-alpha 2b and taurine on oxidative stress markers and hepatocellular apoptosis.
METHODS: Sixty rats with CCl4-induced liver fibrosis were divided into 4 groups (n=15). Group 1 was left for spontaneous recovery (SR). Groups 2-4 received peginterferon-alpha 2b, taurine, and their combination, respectively, for four weeks. Histological fibrosis scores, histomorphometric analysis, tissue hydroxyproline, tissue MDA, GPx and SOD activities were determined. Activated stellate cells and hepatocellular apoptosis were also evaluated.
RESULTS: The degree of fibrosis decreased in all treatment groups compared to spontaneous recovery group. Taurine alone and in combination with peginterferon-alpha 2b reduced oxidative stress markers, but peginterferon-alpha 2b alone did not. Apoptotic hepatocytes and activated stellate cells were higher in groups 2-4 than in group 1. Combined taurine and peginterferon-alpha 2b further reduced fibrosis and increased activated stellate cell apoptosis, but could not improve oxidative stress more than taurine alone.
CONCLUSION: Peginterferon-alpha 2b exerts anti-fibrotic effects on rat liver fibrosis. It seems ineffective against oxidative stress in vivo. Peginterferon-alpha 2b in combination with taurine seems to be an antifibrotic strategy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17589904      PMCID: PMC4436611          DOI: 10.3748/wjg.v13.i23.3237

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  68 in total

1.  Is liver fibrosis reversible?

Authors:  P A Bonis; S L Friedman; M M Kaplan
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

2.  Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control.

Authors:  A Aydin; H Orhan; A Sayal; M Ozata; G Sahin; A Işimer
Journal:  Clin Biochem       Date:  2001-02       Impact factor: 3.281

3.  Effects of interferon-alpha on expression of hepatic stellate cell and transforming growth factor-beta1 and alpha-smooth muscle actin in rats with hepatic fibrosis.

Authors:  Xin-Ming Chang; Ying Chang; Ai Jia
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

4.  Antioxidants vitamin E and C attenuate hepatic fibrosis in biliary-obstructed rats.

Authors:  Ali-Riza Soylu; Nurettin Aydogdu; Umit-Nusret Basaran; Semsi Altaner; Orhan Tarcin; Nursal Gedik; Hasan Umit; Ahmet Tezel; Gulbin Dokmeci; Huseyin Baloglu; Mevlut Ture; Kemal Kutlu; Kadir Kaymak
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

5.  A critical role for alveolar macrophages in elicitation of pulmonary immune fibrosis.

Authors:  J Zhang-Hoover; A Sutton; N van Rooijen; J Stein-Streilein
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

6.  Fibrogenic effect of oxidative stress on rat hepatic stellate cells.

Authors:  G Svegliati Baroni; L D'Ambrosio; G Ferretti; A Casini; A Di Sario; R Salzano; F Ridolfi; S Saccomanno; A M Jezequel; A Benedetti
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

7.  Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells.

Authors:  G Svegliati-Baroni; S Saccomanno; H van Goor; P Jansen; A Benedetti; H Moshage
Journal:  Liver       Date:  2001-02

Review 8.  Molecular therapy for hepatic injury and fibrosis: where are we?

Authors:  Colette C Prosser; Roy D Yen; Jian Wu
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

Review 9.  Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites:implications in inflammation.

Authors:  M B Grisham; D Jourd'Heuil; D A Wink
Journal:  Am J Physiol       Date:  1999-02

10.  Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.

Authors:  N Hiramatsu; N Hayashi; A Kasahara; H Hagiwara; T Takehara; Y Haruna; M Naito; H Fusamoto; T Kamada
Journal:  J Hepatol       Date:  1995-02       Impact factor: 25.083

View more
  10 in total

1.  Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure.

Authors:  Olav Albert Christophersen
Journal:  Microb Ecol Health Dis       Date:  2012-02-01

2.  Extracellular Matrix Remodeling and Modulation of Inflammation and Oxidative Stress by Sulforaphane in Experimental Diabetic Peripheral Neuropathy.

Authors:  Passant E Moustafa; Noha F Abdelkader; Sally A El Awdan; Osama A El-Shabrawy; Hala F Zaki
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

3.  Effects of blueberry on hepatic fibrosis and transcription factor Nrf2 in rats.

Authors:  Yu-Ping Wang; Ming-Liang Cheng; Bao-Fang Zhang; Mao Mu; Jun Wu
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

Review 4.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

5.  Favorable outcome of extended treatment with adding pegylated Interferonα-2a to entecavir for HBeAg-positive chronic hepatitis B: a case report.

Authors:  Ying Zhang; Xuefeng Li; Jiao Xu; Yong Zhang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

6.  Ultrastructural changes in hepatocytes after taurine treatment in CCl4 induced liver injury.

Authors:  Ilker Tasci; Nuket Mas; Mehmet-Refik Mas; Murvet Tuncer; Bilgin Comert
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

7.  Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological marker of non‑alcoholic fatty liver disease.

Authors:  Hemin Jiang; Yu Qian; Ziyang Shen; Yuwei Liu; Yunqiang He; Rui Gao; Min Shen; Shu Chen; Qi Fu; Tao Yang
Journal:  Mol Med Rep       Date:  2021-05-06       Impact factor: 2.952

8.  Predicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysis.

Authors:  Baixue Zheng; Looling Tan; Xuejun Mo; Weimiao Yu; Yan Wang; Lisa Tucker-Kellogg; Roy E Welsch; Peter T C So; Hanry Yu
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

9.  Novel protective role of curcumin and taurine combination against experimental hepatocarcinogenesis.

Authors:  Motawa Eisa El-Houseini; Ibrahim Ali El-Agoza; Mona Mohamed Sakr; Ghada Mohamed El-Malky
Journal:  Exp Ther Med       Date:  2016-12-02       Impact factor: 2.447

10.  Protective efficiacy of taurine against pulmonary edema progression: experimental study.

Authors:  Orhan Yucel; Zeki Ilker Kunak; Enis Macit; Armagan Gunal; Alper Gozubuyuk; Husamettin Gul; Onur Genc
Journal:  J Cardiothorac Surg       Date:  2008-10-28       Impact factor: 1.637

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.